These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667 [TBL] [Abstract][Full Text] [Related]
45. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Inwards DJ; Fishkin PA; Hillman DW; Brown DW; Ansell SM; Kurtin PJ; Fonseca R; Morton RF; Veeder MH; Witzig TE Cancer; 2008 Jul; 113(1):108-16. PubMed ID: 18470909 [TBL] [Abstract][Full Text] [Related]
51. Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Peinert S; Tam CS; Prince HM; Scarlett J; Wolf MM; Januszewicz EH; Westerman D; Seymour JF Leuk Lymphoma; 2010 Dec; 51(12):2188-97. PubMed ID: 20939696 [TBL] [Abstract][Full Text] [Related]
53. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Gertz MA; Rue M; Blood E; Kaminer LS; Vesole DH; Greipp PR Leuk Lymphoma; 2004 Oct; 45(10):2047-55. PubMed ID: 15370249 [TBL] [Abstract][Full Text] [Related]
54. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778 [TBL] [Abstract][Full Text] [Related]
55. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Betticher DC; Hsu Schmitz SF; Ratschiller D; von Rohr A; Egger T; Pugin P; Stalder M; Hess U; Fey MF; Cerny T Br J Haematol; 1997 Nov; 99(2):358-63. PubMed ID: 9375754 [TBL] [Abstract][Full Text] [Related]
56. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Gavriatopoulou M; García-Sanz R; Kastritis E; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Sonneveld P; Dimopoulos MA Blood; 2017 Jan; 129(4):456-459. PubMed ID: 27872060 [TBL] [Abstract][Full Text] [Related]
57. Severe neuropathy in a patient with Waldenstrom disease: from a challenging diagnosis to clinical improvement by innovative therapy. Bertazzoni P; Andreola G; Laszlo D; Agazzi A; Bassi S; Gigli F; Martinelli G Leuk Lymphoma; 2006 Sep; 47(9):1970-2. PubMed ID: 17065016 [No Abstract] [Full Text] [Related]
58. Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Van Den Neste E; Louviaux I; Michaux JL; Delannoy A; Michaux L; Sonet A; Bosly A; Doyen C; Mineur P; André M; Straetmans N; Coche E; Venet C; Duprez T; Ferrant A Leukemia; 2000 Jun; 14(6):1136-42. PubMed ID: 10865980 [TBL] [Abstract][Full Text] [Related]
59. [Osteonecrosis developing after rituximab-containing chemotherapy for Waldenström macroglobulinemia]. Nakamura F; Hirai R; Higo T; Togano T; Sekine R Rinsho Ketsueki; 2018; 59(3):305-309. PubMed ID: 29618689 [TBL] [Abstract][Full Text] [Related]
60. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Treon SP; Tripsas CK; Meid K; Kanan S; Sheehy P; Chuma S; Xu L; Cao Y; Yang G; Liu X; Patterson CJ; Warren D; Hunter ZR; Turnbull B; Ghobrial IM; Castillo JJ Blood; 2014 Jul; 124(4):503-10. PubMed ID: 24859363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]